Literature DB >> 3147701

Mechanisms of pathogenicity in mycobacteria.

N Rastogi1, H L David.   

Abstract

The purpose of this article is to review current knowledge about the mechanisms of pathogenicity of mycobacteria. The following aspects of the problem are discussed: chemically-defined compounds implicated in the mechanisms of pathogenicity; location in the cell wall of these compounds and their biological activities; mechanisms of intracellular survival of pathogenic mycobacteria as compared to intracellular killing of non-pathogenic mycobacteria; and pathogenesis of mycobacterial infection. The future prospects in the elucidation of the mechanisms of pathogenicity and their possible application for a better control of mycobacterial diseases are briefly discussed.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3147701     DOI: 10.1016/0300-9084(88)90272-6

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  20 in total

1.  In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins.

Authors:  H Saito; H Tomioka; K Sato; M Emori; T Yamane; K Yamashita; K Hosoe; T Hidaka
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Elements of signal transduction in Mycobacterium tuberculosis: in vitro phosphorylation and in vivo expression of the response regulator MtrA.

Authors:  L E Via; R Curcic; M H Mudd; S Dhandayuthapani; R J Ulmer; V Deretic
Journal:  J Bacteriol       Date:  1996-06       Impact factor: 3.490

Review 3.  Techniques for genetic engineering in mycobacteria. Alternative host strains, DNA-transfer systems and vectors.

Authors:  J Hermans; J A de Bont
Journal:  Antonie Van Leeuwenhoek       Date:  1996-04       Impact factor: 2.271

Review 4.  Epidemiology of infection by nontuberculous mycobacteria.

Authors:  J O Falkinham
Journal:  Clin Microbiol Rev       Date:  1996-04       Impact factor: 26.132

5.  Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages.

Authors:  N Rastogi; V Labrousse; K S Goh; J P De Sousa
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

6.  Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice.

Authors:  P Deol; G K Khuller; K Joshi
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

7.  Expression of IL-18 by Mycobacterium avium-infected human monocytes; association with M. avium virulence.

Authors:  H Shiratsuchi; J J Ellner
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

8.  Molecular packing of cord factor and its interaction with phosphatidylinositol in mixed monolayers.

Authors:  R Almog; C A Mannella
Journal:  Biophys J       Date:  1996-12       Impact factor: 4.033

9.  Intramacrophagic Mycobacterium avium bacilli are coated by a multiple lamellar structure: freeze fracture analysis of infected mouse liver.

Authors:  S Rulong; A P Aguas; P P da Silva; M T Silva
Journal:  Infect Immun       Date:  1991-11       Impact factor: 3.441

10.  Reevaluation of envelope profiles and cytoplasmic ultrastructure of mycobacteria processed by conventional embedding and freeze-substitution protocols.

Authors:  T R Paul; T J Beveridge
Journal:  J Bacteriol       Date:  1992-10       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.